Kenneth S. Cohen to Treatment Outcome
This is a "connection" page, showing publications Kenneth S. Cohen has written about Treatment Outcome.
Connection Strength
0.338
-
Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011 Mar; 13(3):317-23.
Score: 0.040
-
Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011 Apr; 13(4):410-6.
Score: 0.040
-
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. Haematologica. 2022 07 01; 107(7):1608-1618.
Score: 0.022
-
Is there a requirement for adjuvant therapy for choroid plexus carcinoma that has been completely resected? J Neurooncol. 2002 Apr; 57(2):123-6.
Score: 0.022
-
Pediatric glial tumors. Curr Treat Options Oncol. 2001 Dec; 2(6):529-36.
Score: 0.021
-
Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg. 2001 May; 34(5):229-34.
Score: 0.020
-
A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021 02; 68(2):e28787.
Score: 0.020
-
Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020 06; 21(6):e330-e336.
Score: 0.019
-
Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019 12 15; 25(24):7303-7311.
Score: 0.019
-
A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors. Clin Cancer Res. 2019 12 15; 25(24):7294-7302.
Score: 0.018
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.017
-
Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol. 2016 Sep; 22(6):320-3.
Score: 0.015
-
Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial Efficiency. J Pediatr Hematol Oncol. 2016 07; 38(5):360-6.
Score: 0.015
-
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 2014 Oct; 16(10):1408-16.
Score: 0.013
-
Management of pediatric spinal cord astrocytomas: outcomes with adjuvant radiation. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1307-11.
Score: 0.012
-
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study. Cancer. 2007 Dec 01; 110(11):2535-41.
Score: 0.008
-
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer. Nat Clin Pract Oncol. 2007 May; 4(5):316-21.
Score: 0.008
-
No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediatr Oncol. 2000 Jul; 35(1):80-2.
Score: 0.005
-
Pediatric neuroblastic brain tumors containing abundant neuropil and true rosettes. Pediatr Dev Pathol. 2000 Jul-Aug; 3(4):346-52.
Score: 0.005